Clinical Trial Update: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of GSK2881078 in Single and Repeat Doses [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics of GSK2881078 in single and repeat doses for cachexia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cachexia

Drugs mentioned

• GSK2881078 (GSK2881078)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Cachexia | Phase 1 | Status: COMPLETED